NCT04232514

Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects

A Open-label, Single Center Drug Interaction Study Between HEC74647PA Capsule and HEC110114 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Sunshine Lake Pharma Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of HEC74647 combined with HEC110114 in healthy subjects

Detailed description

This is a 2-part study with each part is an open-label study in healthy adult subjects. Total 28 subjects will be enrolled into the study and divided into 2 part (Part A and Part B), 14 subjects in each part. With each part, the subject will be receive study drug per the defined treatment periods of Day 1\~7 and Day 13\~19.

Conditions

• Chronic Hepatitis C

Interventions

Type	Name	Description
DRUG	HEC74647	Administered HEC74647 200 mg orally once daily in fed state
DRUG	HEC110114	Administered HEC110114 800 mg orally once daily in fed state

Timeline

• Start date: 2020-07-15
• Primary completion: 2020-08-10
• Completion: 2020-08-22
• First posted: 2020-01-18
• Last updated: 2020-11-05

Locations

1 site across 1 country: China